Google Inc vs Vaxcyte Inc. Common Stock — how do they compare? Google Inc trades at $338.8 (market cap $4.30T), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Google Inc is far larger — about 409.1× Vaxcyte Inc. Common Stock's market cap, and Google Inc pays a 0.25% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 138 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GOOG | PCVX | |
|---|---|---|
Market Cap | $4.30T | $10.51B |
Volume | 14,394,061 | 2,644,694 |
Sector | Media | Health |
52-Week High | $399.06 | $73.82 |
52-Week Low | $251.34 | $40.32 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $4.19T | $9.14B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $349.52, up 0.16% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $435.29 highlight investor confidence, though high capital expenditures and legal challenges present near-term risks.
The outlook for GOOG remains positive driven by AI and cloud expansion, with projected 2026 revenue of $445.9 billion. However, rising capex leading to negative free cash flow projections and ongoing securities lawsuits pose significant risks. The stock's current valuation metrics, including a P/E of 17.54, suggest room for growth if execution continues, but investors should weigh these factors against the competitive and regulatory landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →